A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Onvansertib (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms UNITE
- Sponsors TrovaGene
- 18 Oct 2018 According to a TrovaGene media release, the company will present an updated data from this study at a a live conference call and webcast.
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 According to a Trovagene media release, the trial was accepted by the National Library of Medicine (NLM).